Melanoma-associated antigen 1 peptide-HLA-A complex (MAGE-A1/HLA-A)

Melanoma-associated antigen 1 (MAGE-A1) is a pioneering member of the cancer-testis antigen (CTA) family, characterized by its restricted expression in immune-privileged sites like the testis and its aberrant re-expression in various cancers (UniProt P43355). The MAGE-A1 protein is processed intracellularly into short peptides, such as the HLA-A1-restricted EADPTGHSY or HLA-A2-restricted FLWGPRALV, which are then presented on the cell surface by Human Leukocyte Antigen (HLA) class I molecules (Van der Bruggen et al., 1991; PubMed 10449776). This peptide-HLA complex serves as a highly specific target for the immune system, as the normal tissues expressing MAGE-A1 lack the MHC molecules necessary for presentation. Therapeutic strategies targeting this complex include T-cell receptor (TCR) engineered T-cell therapies, such as TK-8001, and cancer vaccines designed to elicit a robust cytotoxic T-lymphocyte response (T-knife Therapeutics, 2024). While MAGE-A1 was the first human tumor antigen identified to be recognized by T cells, clinical development requires careful screening for HLA-type compatibility and potential cross-reactivity with other MAGE family members to ensure safety and efficacy (ClinicalTrials.gov).

Other names

MAGE-1MAGEA1Cancer/testis antigen 1.1CT1.1Antigen MZ2-EMelanoma-associated antigen 1 peptide-HLA-A1 complexMelanoma-associated antigen 1 peptide-HLA-A2 complex

T-cell receptor (TCR) binding to the peptide-MHC complex, leading to T-cell activation and targeted lysis of tumor cells.